undamentalytics Newsletter
Sign in

NRX Pharmaceuticals, Inc. income statement

In fiscal 2025, NRX Pharmaceuticals, Inc. reported revenue of $1.2m, operating income of −$16.2m (a -1324.4% margin) and net income of −$28.6m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0013
Cost of revenue—012
Gross profit—012
Research and development13645
Selling, general and administrative—141316
General and administrative14———
Operating income−28−19−16−20
Interest expense0011
Income tax0000
Net income−30−25−29−23
Diluted shares (average)15m21m21m—
EBITDA−28−18−16−20

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NRXP vs XBIONRXP vs UPBALGS vs NRXP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from NRX Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to NRX Pharmaceuticals, Inc.